leadf
logo-loader
viewImugene Ltd

Imugene to virtually present its immuno-oncology clinical plans at Cancer Research 2020

The first-in-human phase 1 study of Vaxinia is in patients with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.

Imugene Ltd - Imugene to virtually present its immuno-oncology clinical plans at Cancer Research 2020
PD1-Vaxx is targeting patients with non-small cell lung cancer

Imugene Limited (ASX:IMU) will present the clinical plans for its cancer immunotherapy and oncolytic virus at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I, scheduled for April 27th-28th 2020.

Vaxinia

Dr Seymour Fein will present the clinical plan for the initial trial of Imugene’s oncolytic virus, Vaxinia (CF33-hNIS), at the AACR 2020 Virtual Annual Meeting.

The abstract presentation is entitled ‘A first-in-human phase 1 ascending, multiple dose, safety and tolerance study of Vaxinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adult patients with mixed advanced solid tumors (MAST)’, and was authored by Dr Fein and Imugene.

The first-in-human, phase 1, multi-centre, dose escalation study of Vaxinia (CF33-hNIS), is investigating intratumoural and intravenous administration lines as monotherapy and in combination with immune checkpoint inhibitors in a patient population with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.

The primary objectives of the phase 1 trial are to determine safety and a recommended phase 2 dose as monotherapy and in combination with immune checkpoint inhibitors.

Efficacy and immune responses will also be measured.

PD1-Vaxx

Dr Anthony Good will present the clinical plan for Imugene’s PD-1 targeting cancer immunotherapy, PD1-Vaxx, at the AACR 2020 Virtual Annual Meeting.

The abstract presentation is entitled ‘IMU-201-101 an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer’.

The first-in-human, phase 1, multi-centre, dose escalation study of PD1-Vaxx, is targeting patients with non-small cell lung cancer and will be testing different doses of PD1-Vaxx as monotherapy and in combination with immune checkpoint inhibitors.

The primary objective of the phase 1 trial is to determine safety and an optimal biological dose as monotherapy and in combination with immune checkpoint inhibitors.

Efficacy, tolerability and immune response will also be measured.

Quick facts: Imugene Ltd

Price: 0.048 AUD

ASX:IMU
Market: ASX
Market Cap: $215.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

on 20/7/20

2 min read